Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose -- Ignore unavailable to you. Want to Upgrade?

To: JOHN WHITE who wrote (1405)	8/1/1998 1:37:00 PM
From: thomas alta	Respond to of 4650

From Biomoda Web page.-----generation products: Reagents for diagnosing cancer in tissue specimens as performed in the cytology laboratory. In Vivo/Second-generation products: TCPP complexed with radioactive copper. Two separate formulations will be used; one for diagnosing and the other for treating lung cancer. DOES THE ABOVE MEAN THESE REAGENTS CAN BE USED IN ALL TISSUE BIOPSIES TO RULE OUT CANCER-------TOM MARKET POTENTIAL:According to the Theta Research Corporation, the cancer therapeutics market is expected to exceed $3 billion by 1998. The in vivo imaging and radiopharmaceutical market is expected to exceed $1.3 billion. KEY MANAGEMENT:Ari Ma'ayan - President and Chief Executive Officer